PMID- 32430419
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1399-3003 (Electronic)
IS  - 0903-1936 (Linking)
VI  - 56
IP  - 2
DP  - 2020 Aug
TI  - Cardiac function and pulmonary hypertension in Central Asian highlanders at 
      3250 m.
LID - 1902474 [pii]
LID - 10.1183/13993003.02474-2019 [doi]
AB  - THE QUESTION ADDRESSED BY THE STUDY: Chronic exposure to hypoxia increases 
      pulmonary artery pressure (PAP) in highlanders, but the criteria for diagnosis of 
      high-altitude pulmonary hypertension (HAPH) are debated. We assessed cardiac 
      function and PAP in highlanders at 3250 m and explored HAPH prevalence using 
      different definitions. PATIENTS AND METHODS: Central Asian highlanders free of 
      overt cardiorespiratory disease, permanently living at 2500-3500 m compared to 
      age-matched lowlanders living <800 m. Participants underwent echocardiography 
      close to their altitude of residence (at 3250 m versus 760 m). RESULTS: 173 
      participants (97 highlanders, 76 lowlanders), mean+/-sd age 49+/-9 years (49% 
      females) completed the study. Results in lowlanders versus highlanders were 
      systolic PAP (23+/-5 versus 30+/-10 mmHg), right ventricular fractional area change 
      (42+/-6% versus 39+/-8%), tricuspid annular plane systolic excursion (2.1+/-0.3 versus 
      2.0+/-0.3 cm), right atrial volume index (20+/-6 versus 23+/-8 mL.m(-2)), left 
      ventricular ejection fraction (62+/-4% versus 57+/-5%) and stroke volume (64+/-10 
      versus 57+/-11 mL); all between-group comparisons p<0.05. Depending on criteria, 
      HAPH prevalence varied between 6% and 35%. THE ANSWER TO THE QUESTION: Chronic 
      exposure to hypoxia in highlanders is associated with higher PAP and slight 
      alterations in right and left heart function compared to lowlanders. The 
      prevalence of HAPH in this large highlander cohort varies between 6% according to 
      expert consensus definition of chronic high-altitude disease to 35% according to 
      the most recent definition of pulmonary hypertension proposed for lowlanders.
CI  - Copyright (c)ERS 2020.
FAU - Lichtblau, Mona
AU  - Lichtblau M
AUID- ORCID: 0000-0003-4485-1758
AD  - Dept of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
AD  - Both authors contributed equally.
FAU - Saxer, Stephanie
AU  - Saxer S
AUID- ORCID: 0000-0002-5250-5022
AD  - Dept of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
AD  - Both authors contributed equally.
FAU - Furian, Michael
AU  - Furian M
AUID- ORCID: 0000-0002-8518-5029
AD  - Dept of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
FAU - Mayer, Laura
AU  - Mayer L
AD  - Dept of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
FAU - Bader, Patrick R
AU  - Bader PR
AD  - Dept of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
FAU - Scheiwiller, Philipp M
AU  - Scheiwiller PM
AD  - Dept of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
FAU - Mademilov, Maamed
AU  - Mademilov M
AD  - National Center for Cardiology and Internal Medicine, Bishkek, Kyrgyzstan.
FAU - Sheraliev, Ulan
AU  - Sheraliev U
AD  - National Center for Cardiology and Internal Medicine, Bishkek, Kyrgyzstan.
FAU - Tanner, Felix C
AU  - Tanner FC
AD  - Dept of Cardiology, University Hospital Zurich, Zurich, Switzerland.
FAU - Sooronbaev, Talant M
AU  - Sooronbaev TM
AD  - National Center for Cardiology and Internal Medicine, Bishkek, Kyrgyzstan.
FAU - Bloch, Konrad E
AU  - Bloch KE
AD  - Dept of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
FAU - Ulrich, Silvia
AU  - Ulrich S
AD  - Dept of Pulmonology, University Hospital Zurich, Zurich, Switzerland 
      silvia.ulrich@usz.ch.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - Eur Respir J
JT  - The European respiratory journal
JID - 8803460
SB  - IM
MH  - Adult
MH  - Altitude
MH  - *Altitude Sickness
MH  - Female
MH  - Humans
MH  - *Hypertension, Pulmonary/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Stroke Volume
MH  - Ventricular Function, Left
COIS- Conflict of interest: M. Lichtblau has nothing to disclose. Conflict of interest: 
      S. Saxer has nothing to disclose. Conflict of interest: M. Furian has nothing to 
      disclose. Conflict of interest: L. Mayer has nothing to disclose. Conflict of 
      interest: P.R. Bader has nothing to disclose. Conflict of interest: P.M. 
      Scheiwiller has nothing to disclose. Conflict of interest: M. Mademilov has 
      nothing to disclose. Conflict of interest: U. Sheraliev has nothing to disclose. 
      Conflict of interest: F.C. Tanner has nothing to disclose. Conflict of interest: 
      T.M. Sooronbaev has nothing to disclose. Conflict of interest: K.E. Bloch reports 
      grants from Zurich Lung League and Swiss National Science Foundation, during the 
      conduct of the study. Conflict of interest: S. Ulrich reports grants from Zurich 
      Lung League and Swiss National Science Foundation, during the conduct of the 
      study; grants and personal fees from Actelion SA and Orpha Swiss, personal fees 
      from Bayer SA and MSD, outside the submitted work.
EDAT- 2020/05/21 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/01/07 00:00 [received]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/21 06:00 [entrez]
AID - 13993003.02474-2019 [pii]
AID - 10.1183/13993003.02474-2019 [doi]
PST - epublish
SO  - Eur Respir J. 2020 Aug 20;56(2):1902474. doi: 10.1183/13993003.02474-2019. Print 
      2020 Aug.